Results 91 to 100 of about 28,175 (193)
Transplant Infectious Disease, EarlyView.Among 135 cases of post‐liver transplant HHV8 disease (4 from NSW), presentations varied, and mortality was high (44%). Donor screening was rare, and donor‐derived infection was suspected in 33%. Survival improved with mTORi, reduced immunosuppression, chemotherapy, and, for non‐KS disease, donor screening. ABSTRACT Background Human herpesvirus 8 (HHV8)
Karen M. J. Waller +12 more
wiley +1 more source
International Journal of Cancer, Volume 159, Issue 7, Page 1735-1749, 1 October 2026.The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg +9 more
wiley +1 more source
Journal of Veterinary Internal MedicineBackground Romiplostim, a thrombopoietin analog, is commonly used to treat immune‐mediated thrombocytopenia (ITP) in humans, but its use in dogs remains limited.
Min‐Ok Ryu +5 more
doaj +1 more source
International Journal of Cancer, Volume 159, Issue 6, Page 1499-1509, 15 September 2026.Primary central nervous system diffuse large B‐cell lymphoma (PCNS‐DLBCL) lacks an optimal first‐line induction strategy, particularly for older patients and those ineligible for intensive consolidation. In this retrospective cohort of 36 newly diagnosed patients, the rituximab + methotrexate + thiotepa (RMT) regimen as first‐line induction achieved ...
Haotian Wang +10 more
wiley +1 more source
Clinically Relevant Bleeding in Individuals With Cancer: Insights From a Nationwide Cohort Study
American Journal of Hematology, Volume 101, Issue 9, Page 2123-2136, September 2026.ABSTRACT Cancer care is often complicated by coagulopathy leading to thrombosis and bleeding. While venous thromboembolism (VTE) has been extensively studied, bleeding remains an underestimated threat. To address this knowledge gap, we leveraged the Epic Cosmos database to determine the impact of cancer‐associated clinically relevant bleeding (CRB) in ...
Ming Y. Lim +11 more
wiley +1 more source
Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk‐Stratification and Management
American Journal of Hematology, Volume 101, Issue 9, Page 2393-2411, September 2026.ABSTRACT Disease Overview The myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older males and in individuals with prior exposure to cytotoxic therapy.
Guillermo Garcia‐Manero
wiley +1 more source
Thrombopoietin-Receptor Agonism in Chemotherapy-Induced Thrombocytopenia
International Journal of Contemporary PathologyChemotherapy-induced thrombocytopenia (CIT) is a common, dose-limiting toxicity of cytotoxic cancer therapy that frequently necessitates dose reduction, delay, or discontinuation, thereby compromising relative dose intensity and potentially diminishing therapeutic efficacy. Existing management strategies are largely supportive and do not address the
openaire +1 more source
American Journal of Hematology, Volume 101, Issue 9, Page 2258-2268, September 2026.ABSTRACT Quizartinib is a tyrosine kinase inhibitor with single agent activity in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and has demonstrated efficacy in first‐line therapy when combined with intensive chemotherapy in both FLT3 ITD‐negative and positive AML.
Teresa Bernal +29 more
wiley +1 more source
Marked Bone Marrow Eosinophilia Post‐Azacitidine + Ivosidenib Treatment for Acute Myeloid Leukemia
International Journal of Laboratory Hematology, EarlyView.
Christopher Liwski +2 more
wiley +1 more source